Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP089: Shaping the Future of IBD Diagnostics: A Multicentric AI-Driven Capsule Endoscopy StudyECCO'25 Berlin
Year: 2025
Authors: Mendes, Francisco
DOP090: Serum metabolites predict endoscopic disease activity and clinical and endoscopic remission in Ulcerative ColitisECCO'25 Berlin
Year: 2025
Authors: Welz, Lina
DOP091: Early serum infliximab levels predict outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UCECCO'25 Berlin
Year: 2025
Authors: Li Wai Suen, Christopher
DOP092: Efficacy and safety of a second JAK inhibitor in Ulcerative Colitis : J2J multicenter cohortECCO'25 Berlin
Year: 2025
Authors: Uzzan, Mathieu
DOP093: ECCO Topical Review on predictive models for IBD disease course and treatment responseECCO'25 Berlin
Year: 2025
Authors: Kirchgesner, Julien
DOP094: Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trialECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
DOP095: IL-23-activated cells as response biomarkers for risankizumab in Crohn’s disease patientsECCO'25 Berlin
Year: 2025
Authors: Cao, Siyan
DOP096: Durability of TNF inhibitors in Crohn’s disease patients does not change with prior use of non-TNF agentsECCO'25 Berlin
Year: 2025
Authors: Cohen, Ella
DOP097: Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial - a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patientsECCO'25 Berlin
Year: 2025
Authors: Bancil, Aaron
DOP099: Prolonged Pharmacodynamic Effects of Risankizumab Following Withdrawal in Patients with Moderately to Severely Active Ulcerative ColitisECCO'25 Berlin
Year: 2025
Authors: Demasi, Ryan
DOP100: RXC008, a first-in-class gastrointestinal restricted pan-ROCK inhibitor developed for treatment of intestinal fibrosis shows GI restriction and tolerability: Results from the phase 1 program in healthy participants.ECCO'25 Berlin
Year: 2025
Authors: Rieder, Florian
DOP101: Maintaining remission after an episode of steroid-responsive Acute Severe Ulcerative Colitis: what is the best strategy?ECCO'25 Berlin
Year: 2025
Authors: Bravo, Catarina
DOP102: Comparative effectiveness of risankizumab vs. ustekinumab in bio-naïve Crohn's disease patients: A real-world multicentre retrospective cohort studyECCO'25 Berlin
Year: 2025
Authors: Deepak, Parakkal
DOP103: Optimization of Ustekinumab Treatment Induction Using a Pharmacokinetic Model in Inflammatory Bowel Disease Patients.ECCO'25 Berlin
Year: 2025
Authors: Ramos Lopez, Laura
DOP104: International differences in pre-operative characteristics and postoperative management in patients with Crohn’s disease following ileocolic resection: a report from the IMPACT consortiumECCO'25 Berlin
Year: 2025
Authors: Bak, Michiel
DOP105: Patient-reported quality of life in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Insights from the communicating needs and features of IBD experiences (CONFIDE) surveyECCO'25 Berlin
Year: 2025
Authors: Schreiber, Stefan Wolfgang
DOP106: Geographic disparities in Healthcare Utilisation in people with inflammatory bowel disease, Crohn’s Colitis Cure Data Insights ProgramECCO'25 Berlin
Year: 2025
Authors: Andrews, Jane Mary
DOP107: Real-time intestinal barrier assessment by endocytoscopy and confocal laser endomicroscopy uniquely correlates with multiple barrier protein expression and reflects the gut-brain axisECCO'25 Berlin
Year: 2025
Authors: Iacucci, Marietta
DOP108: Inflammatory Bowel Disease and concomitant endometriosis: frequency and characteristics in a multidisciplinary approachECCO'25 Berlin
Year: 2025
Authors: Neri, Benedetto
DOP109: A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel diseaseECCO'25 Berlin
Year: 2025
Authors: Christensen, Britt